ReviewWorld journal of hepatology2015
Hepatitis C and kidney disease: An overview and approach to management.
Review in World journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 58 citations in OpenAlex.
- Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials.European journal of clinical pharmacology · 2019Trial
- Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.Hepatology (Baltimore, Md.) · 2018Trial
- Factors associated with chronic kidney disease among patients with hepatitis c infection attending Kigeme district hospital, Rwanda.Scientific reports · 2026Article
- Elimination of hepatitis C in the Middle East: a narrative review of the efficacy of direct-acting antiviral therapies.Translational gastroenterology and hepatology · 2025Review
- The effect of anemia on the efficacy and safety of treating chronic hepatitis C infection with direct-acting antivirals in patients with chronic kidney disease.International urology and nephrology · 2021Article
- Tubular cell damage may be the earliest sign of renal extrahepatic manifestation caused by Hepatitis C.PloS one · 2021Article
- Impact of HIV and chronic kidney disease comorbidities on hepatitis C treatment choices, drug-drug interactions and hepatitis C cure.International journal of clinical pharmacy · 2020Observational
- Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease.BMC nephrology · 2020Observational
- Use of sofosbuvir based regimen in patients with end-stage renal disease and chronic hepatitis C; an open label, non-randomized, single arm, single center study from Pakistan.Gastroenterology and hepatology from bed to bench · 2020Article
- Sociodemographic and clinical characteristics of persons who experienced spontaneous hepatitis C viral clearance.BMC infectious diseases · 2019Article
- HCV Extrahepatic Manifestations.Journal of clinical and translational hepatology · 2019Review
- Anti-hepatitis C virus therapy in chronic kidney disease patients improves long-term renal and patient survivals.World journal of clinical cases · 2019Article
- Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan.Medicina (Kaunas, Lithuania) · 2018Review
- Hepatitis C Virus Treatment in Patients With Chronic Kidney Disease and in Kidney Transplant Recipients.Gastroenterology & hepatology · 2018Article
- Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD.Hepatology (Baltimore, Md.) · 2018Article
- Successful recovery of associated interstitial nephritis and focal segmental glomerulosclerosis in patients with HCV and HIV treated with sofosbuvir and daclatasvir and revision of literature.Clinical nephrology. Case studies · 2018Article
- Project HELP: a study protocol to pilot test a shared decision-making tool about treatment options for patients with hepatitis C and chronic kidney disease.Pilot and feasibility studies · 2018Article
- Reducing major risk factors for chronic kidney disease.Kidney international supplements · 2017Review
- Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection.Hepatology (Baltimore, Md.) · 2017Article
- Is the 25-year hepatitis C marathon coming to an end to declare victory?World journal of hepatology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C infection and chronic kidney disease are major health burden worldwide. Hepatitis C infection is associated with a wide range of extra-hepatic manifestations in various organs including the kidneys. A strong association between hepatitis C and chronic kidney disease has come to light. Hemodialysis in supporting the end stage renal disease patients unfortunately carries a risk for hepatitis C infection. Despite much improvement in the care of this group of patients, the prevalence of hepatitis C infection in hemodialysis patients is still higher than the general population. Hepatitis C infection has a negative effect on the survival of hemodialysis and renal transplant patients. Treatment of hepatitis C in end stage renal disease patients using conventional or pegylated interferon with or without ribavirin remains a clinical challenge with low response rate, high dropout rate due to poor tolerability and many unmet needs. The approval of new direct acting antiviral agents for hepatitis C may dramatically change the treatment approach in hepatitis C infected patients with mild to moderate renal impairment. However it remains to be confirmed if the newer Hepatitis C therapies are safe in individuals with severe renal impairment. This review article discusses the relationship between hepatitis C and chronic kidney disease, describe the various types of renal diseases associated with hepatitis C and the newer as well as the existing treatments for hepatitis C in the context of this subpopulation of hepatitis C patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.